Nilotinib – Differentiating the Hope from the Hype
Wyse RK, Brundin P, Sherer TB. (2016) Nilotinib – Differentiating the Hope from the Hype. J Parkinsons Dis. 2016 Jul 12.
View PublicationNilotinib Effects in Parkinson’s Disease and Dementia with Lewy Bodies
Pagan F, Hebron M, Valadez EH, Tores-Yaghi Y, Huang X, Mills RR, Wilmarth BM, Howard H, Dunn C, Carlson A, Lawler A, Rogers SL, Drew Falconer R, Ahn J, Li Z, Moussa C. (2016) Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies. J Parkinsons Dis. 2016 Jul 11.
View PublicationActivation of Tyrosine Kinase c-Abl Contributes to α-synuclein-Induced Neurodegeneration
Brahmachari S, Ge P, Lee SH, Kim D, Karuppagounder SS, Kumar M, Mao X, Shin JH, Lee Y, Pletnikova O, Troncoso JC, Dawson VL, Dawson TM, Ko HS. (2016) Activation of tyrosine kinase c-Abl contributes to α-synuclein-induced neurodegeneration. J Clin Invest. 126:2970-88.
View PublicationTargeting α-synuclein for Treatment of Parkinson’s Disease: Mechanistic and Therapeutic Considerations
Dehay B, Bourdenx M, Gorry P, Przedborski S, Vila M, Hunot S, Singleton A, Olanow CW, Merchant KM, Bezard E, Petsko GA, Meissner WG. (2015) Targeting α-synuclein for treatment of Parkinson’s disease: mechanistic and therapeutic considerations. Lancet Neurol. 14:855-66.
View PublicationNew Tricks for Old Dogs: Countering Antibiotic Resistance in Tuberculosis with Host-directed Therapeutics
Hawn TR, Shah JA, Kalman D. (2015) New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics. Immunol Rev. Mar;264(1):344-62.
View PublicationAnti-JC Virus Antibody Levels in Serum or Plasma Further Define Risk of Natalizumab-associated Progressive Multifocal Leukoencephalopathy
Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S, Schlain B, Campagnolo D, Belachew S, Ticho B. (2014) Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann. Neurol. 76, 802-812.
View Publicationc-Abl Phosphorylates Alpha-synuclein and Regulates its Degradation: Implication for Alpha-synuclein Clearance and Contribution to the Pathogenesis of Parkinson’s Disease
Mahul-Mellier AL, Fauvet B, Gysbers A, Dikiy I, Oueslati A, Georgeon S, Lamontanara AJ, Bisquertt A, Eliezer D, Masliah E, Halliday G, Hantschel O, Lashuel HA. (2014) c-Abl phosphorylates alpha-synuclein and regulates its degradation: implication for alpha-synuclein clearance and contribution to the pathogenesis of Parkinson’s disease. Hum Mol Genet. 23:2858-79.
View PublicationJC Virus in CD34 and CD19 Cells in Patients with Multiple Sclerosis Treated with Natalizumab
Frohman EM, Monaco MC, Remington G, Ryschkewitsch C, Jensen PN, Johnson K, Perkins M, Liebner J, Greenberg B, Monson N, Frohman TC, Douek D, Major EO. (2014) JC virus in CD34 and CD19 cells in patients with multiple sclerosis treated with natalizumab. JAMA Neurol. 71:596 – 602.
View PublicationThe c-Abl Inhibitor, Nilotinib, Protects Dopaminergic Neurons in a Preclinical Animal Model of Parkinson’s Disease
Karuppagounder SS, Brahmachari S, Lee Y, Dawson VL, Dawson TM, Ko HS. (2014) The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson’s disease. Sci Rep. 2014 May 2;4:4874.
View PublicationNeuroprotective Efficacy of a New Brain-penetrating C-Abl Inhibitor in a Murine Parkinson’s Disease Model
Imam SZ, Trickler W, Kimura S, Binienda ZK, Paule MG, Slikker W, Jr., Li S, Clark RA, Ali SF. (2013) Neuroprotective efficacy of a new brain-penetrating C-Abl inhibitor in a murine Parkinson’s disease model. PLoS One. 8:e65129.
View Publication